Peptide Frenzy: A Perfect Storm of Greed and Regulatory Abandon The recent surge in popularity of peptides among bodybuilders and biohackers has been met with reckless enthusiasm from industry insiders, who see the FDA's upcoming meeting as an opportunity to exploit regulatory grey areas.
The July 23 24 meeting will discuss reclassifying certain peptides to allow pharmacies to make custom mixes, potentially paving the way for mass production and sales. This development is not without precedent.
The GLP 1 boom has already proven to be a cash cow for pharmacies and virtual clinics, warming people up to the idea of injecting medications at home.